Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis

Virtually all cases of chronic lymphocytic leukemia (CLL) are preceded by a pre-malignant condition known as monoclonal B-cell lymphocytosis (MBL).1 MBL is defined as a clonal lymphoproliferative disorder with an absolute B-cell count of <5 × 10/L, in the absence of symptoms, organomegaly, and lymphadenopathy.42 MBL is classified into low-count MBL (absolute B-cell count <0.5 × 10/L, identified during population screening studies) and high count MBL (absolute B-cell count ≥0.5 × 10/L, typically identified during the work-up of low-count lymphocytosis).65 Retrospective studies of ~20–300 individuals with MBL and relatively short follow up (median 3.5 years) have reported that the risk of progression to CLL requiring therapy ranges from 1.1% to 5% per year.137 Data regarding risk factors for progression are limited, with some reports suggesting CD38 expression, unmutated immunoglobulin heavy chain (IGHV) genes and high-risk cytogenetic aberrations, as determined by fluorescence in situ hybridization, are associated with a higher risk of progression.1298 However, these analyses are limited by the small numbers of individuals with MBL, short follow-up period and lack of survival analysis. In this study, we describe the outcomes of a large cohort of individuals with high-count MBL seen at the Mayo Clinic.

The Mayo Clinic CLL Database includes adults with a clonal B-cell population of the CLL immunophenotype seen at Mayo Clinic (Rochester, MN, USA) who permit their records to be used for research purposes.1714 Using this database, we identified individuals with clinically ascertained high-count MBL who were seen between January 1, 1995 and May 31, 2016. Individuals with atypical-CLL and non-CLL MBL immunophenotype, and those with a concomitant lymphoproliferative neoplasm within three months of MBL ascertainment were excluded. Indications for treatment were classified into: (i) progression to CLL requiring therapy; (ii) immune complications; (iii) high-grade lymphoma; and (iv) non-MBL related conditions. The percent of bone marrow infiltration by monoclonal B cells among individuals who underwent bone marrow biopsy was recorded. The Mayo Clinic Institutional Review Board approved this study.

Time to first therapy was defined as the time interval between the date of MBL diagnosis and the date of first therapy for an MBL-related reason. Time to first therapy was analyzed using cumulative incidence methods accounting for competing risk of death. Overall survival was estimated by the Kaplan–Meier method and defined as the time from the date of MBL diagnosis until death or last follow up. Multivariable Cox proportional hazards regression analysis was used to identify factors that predicted time to first treatment and overall survival. Because of missing data for some prognostic parameters, multiple models were run, introducing one novel prognostic factor at a time to the base model (consisting of age and sex). Overall survival was compared to the age- and sex-matched population of the state of Minnesota.

Four hundred and forty-five individuals with clinically ascertained high-count MBL were identified. Their median age at the time of diagnosis of MBL was 69 years (range, 44–95 years). Two hundred and sixty-three (59%) were males, and the median absolute B-cell count was 2.9 × 10/L (range, 0.5–4.9 × 10/L) (Table 1). The median infiltration of bone marrow by the B-cell clone was 15% (range, 0–70%) among 52 individuals who underwent a clinical bone marrow biopsy. After a median follow up of 6.4 years, 45 individuals required therapy. Of these 45 individuals, 39 (87%) received treatment for MBL-related reasons (including 32 for progression to CLL requiring therapy; 5 for immune complications, and 2 for high-grade lymphoma) and 6 (13%) for non-MBL-related conditions (Online Supplementary Table S1). When considering MBL-related reasons only as an indication to start treatment, the rate of progression was estimated to be ~1.4% per year (Figure 1A). The estimated 2-, 5- and 10-year incidences of requiring therapy were, respectively, 1.8%, 7.7%, and 22.6% for progressive CLL, 1.3%, 2.0%, and 2.0% for immune complications, and 0.4%, 0.9%, and 0.9% for high-grade lymphoma (Figure 1B).

Table 1.Baseline characteristics of individuals with clinically ascertained monoclonal B-cell lymphocytosis.

Figure 1.Time to first therapy in clinically ascertained high-count monoclonal B-cell lymphocytosis. (A) For the overall cohort. (B) According to reason for therapy (progression to chronic lymphocytic leukemia, immune complications, and high-grade lymphoma).

Of the 32 individuals treated for progression to CLL requiring therapy, 9 (28%) received anti-CD20 monoclonal antibody alone, 8 (25%) received a combination of an alkylator and anti-CD20 monoclonal antibody, 7 (22%) received chemoimmunotherapy, 6 (19%) received an alkylator alone, and 2 (6%) received ibrutinib. Seven individuals received therapy for an indication besides CLL progression: 5 for immune complications (autoimmune hemolytic anemia, n=3; membranoproliferative glomerulonephritis, n=2) and 2 patients with diffuse large B-cell lymphoma. Therapy for autoimmune hemolytic anemia included steroids alone (n=2) and steroids with rituximab (n=1), resulting in complete response in one patient and partial response in 2 patients. Both individuals with glomerulonephritis received rituximab-based therapy and achieved a significant reduction in proteinuria. Two individuals treated for diffuse large B-cell lymphoma, at 17 and 34 months after MBL, received cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab.

The median overall survival of the entire cohort was 11.7 years. Online Supplementary Table S2 shows factors associated with shorter time to first treatment and overall survival on multivariable analysis. After adjusting for age and sex, serum β₂-microglobulin ≥3.5 μg/mL [Hazard Ratio (HR): 6.2, P<0.0001], CD38 ≥30% (HR: 3.5, P<0.0001), unmutated IGHV (HR: 3.1, P=0.003), and CD49d ≥30% (HR: 3.1, P=0.004) were independently associated with shorter time to first treatment. After adjusting for age and sex, serum β₂-microglobulin ≥3.5 μg/mL (HR: 2.7, P=0.002), and unmutated IGHV (HR: 2.4, P=0.004), were independently associated with shorter overall survival. The absolute B-cell count and percent bone marrow infiltration by the B-cell clone were not predictive for time to first treatment or overall survival. The overall survival among individuals with MBL was similar to that of the age- and sex-matched general population of Minnesota (P=0.23) (Figure 2).

Figure 2.Overall survival of individuals with clinically ascertained monoclonal B-cell lymphocytosis compared to the age- and sex-matched general population of Minnesota.

Multiple prior studies evaluating the natural history of MBL have estimated that the risk of progression to CLL requiring therapy is approximately 1–5%.137 Consequently, expert guidelines recommend annual visits for individuals with MBL, with particular focus on physical examination (to detect lymphadenopathy and organomegaly), and a complete blood count to detect worsening lymphocytosis or cytopenias.6 Results from our study confirm the previously reported rate of progression with long-term follow up, and extend our understanding of the reasons for treatment. Consistent with current knowledge, the most common reason for therapy in our study of high-count MBL individuals was progression to CLL. Investigators of the UK Haematological Malignancy Research Network reported that 6/353 (1.7%) individuals with MBL were treated with corticosteroids for an autoimmune complication.18 The findings were similar in our current study in which ~1% individuals with MBL were treated for an immune complication with steroids alone or in combination with anti-CD20 monoclonal antibody. We also observed that a small number of individuals were treated for renal manifestations of the malignant B-cell clone. This observation is similar to the recently described entity of monoclonal gammopathy of renal significance in patients with plasma cell disorders,19 indicating that treatment of the underlying B-cell clone may favorably affect organ function. Finally, a small proportion of individuals with MBL required therapy for a high-grade lymphoma diagnosed ~2 years after the ascertainment of MBL. Collectively, these findings reinforce our suggestion above that clinicians need to be cognizant of disease complications other than CLL progression in individuals with high-count MBL.2120

Although it is not yet clinically indicated to perform prognostic testing in individuals with MBL, results from this study provide important data that biological markers associated with risk of progressive disease in CLL2422 are also associated with risk of progression in MBL. Given that these markers were not available for ~30% of our patients and the limited number of events, we were unable to perform comprehensive modeling (e.g. calculating the CLL-International Prognostic Index)25 in this group of patients. Results from our study confirm prior findings that, as a group, the overall survival of individuals with MBL is similar to that of the age- and sex-matched general population.2610 Multivariable analysis of factors associated with shorter overall survival includes unmutated IGHV genes and high serum β₂-microglobulin, suggesting that the shorter survival may be related to the presence of the B-cell clone. Recent studies have also shown that individuals with MBL have a higher risk of serious infections and non-hematologic malignancies compared to the general population and similar to that of patients with CLL.2120 Preliminary studies from our group have also identified specific immune defects in MBL, including increased exhausted T cells and impaired immunological T-cell synapse formation.27 Although cause of death could not be ascertained in this cohort, one can speculate that adverse biological factors related to the B-cell clone and/or a immune deficits could contribute to shorter survival in MBL.

Our study has several limitations. It is a single-center study and additional studies are needed to demonstrate that the results are generalizable. Individuals with MBL were included in this study based on physical examination findings;2 however, it is possible that some individuals with small lymphocytic lymphoma may have been included, potentially overestimating the risk of disease progression.

In summary, data from our cohort of individuals with clinically ascertained MBL demonstrate that the risk of requiring therapy is ~1.4% per year, after a median follow up of ~6.5 years. In addition to the risk of progression to CLL requiring therapy (7% of the overall cohort), immune complications (1% of the overall cohort) and high-grade lymphoma (0.4% of the overall cohort) are additional indications for therapy. These findings have important implications for counselling individuals with clinically ascertained high-count MBL.